Maspin marker may predict breast cancer relapse:
This article was originally published in Clinica
Executive Summary
Measuring levels of a protein called maspin in certain breast cancer patients could help doctors identify those more likely to suffer a relapse following therapy, according to preliminary results from an Italian study. In an assessment of 48 high-risk breast cancer patients with a micrometastatic disease, those with higher levels of the protein were less likely to relapse, reported researchers from the European Institute of Oncology in Milan. Of 10 women with 20 or more lymph nodes affected by the disease, eight who had high levels of maspin did not relapse at a 15 month-follow-up, while the remaining two with low levels of the protein developed secondary cancers.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.